Human non-Hodgkin's lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21

Blood

Volumn 89, Issue 7, 1997, Pages 2523-2528

  Maestro, Roberta ^b   Gloghini, Annunziata ^b   Doglioni, Claudio ^b   Piccinin, Sara ^b   Vukosavljevic, Tamara ^b   Gasparotto, Daniela ^b   Carbone, Antonino ^b   Boiocchi, Mauro ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0030903430     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.7.2523     Document Type: Article

References (23)

1. Lane DP: Cancer. p53, guardian of the genome. Nature 358:15, 1992
2. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70:523, 1992
3. Ko LJ, Prives C: p53: Puzzle and paradigm. Genes Dev 10:1054, 1996
4. el Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817, 1993
5. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805, 1993
6. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p 21 is a universal inhibitor of cyclin kinases. Nature 366:701, 1993
7. Cho Y, Gorina S, Jeffrey PD, Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265:346, 1994
8. Arrowsmith CH, Morin P: New insights into p53 function from structural studies. Oncogene 12:1379, 1996
9. Maestro R, Gloghini A, Doglioni C, Gasparotto D, Vukosavljevic T, De Re V, Laurino L, Carbone A, Boiocchi M: MDM2 overexpression does not account for stabilization of wild-type p53 protein in noh-Hodgkin's lymphomas. Blood 85:3239, 1995
10. Cesarman E, Inghirami G, Chadburn A, Knowles DM: High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 143:845, 1993
11. Villuendas R, Piris MA, Algara P, Sanchez Beato M, Sanchez Verde L, Martinez JC, Orradre JL, Garcia P, Lopez C, Martinez P: The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 82:3151, 1993
12. De Re V, Carbone A, De Vita S, Gloghini A, Maestro R, Gasparotto D, Vukosavljevic T, Boiocchi M: p53 protein over-expression and p53 gene abnormalities in HIV-1-related non-Hodgkin's lymphomas. Int J Cancer 56:662, 1994
13. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf Peeters C, Falini B, Gatter KC, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
14. Sambrook J, Fritsch EF, Maniatis T: Molecular cloning. A laboratory manual. Plainview, NY, Cold Spring Harbor Laboratory, 1989
15. Dei Tos AP, Maestro R, Doglioni C, Gasparotto D, Boiocchi M, Laurino L, Fletcher CDM: Ultraviolet-induced p53 mutations in atypical fibroxanthoma. Am J Pathol 145:11, 1994
16. Maestro R, Dolcetti R, Gasparotto D, Doglioni C, Pelucchi S, Barzan L, Grandi E, Boiocchi M: High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 7:1159, 1992
17. Bhatia K, Fan S, Spangler G, Weintraub M, O'Connor PM, Judde JG, Magrath I: A mutant p21 cyclin-dependent kinase inhibitor isolated from Burkitt's lymphoma. Cancer Res 55:1431, 1995
18. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54:3391, 1994
19. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9:935, 1995
20. Zhang H, Hannon GJ, Beach D: p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 8:1750, 1994
21. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97, 1996
22. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann Hieb E, De Plaen E, Hankeln T, Meyer zum Buschenfelde KH, Beach D: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281, 1995
23. Hermeking H, Funk JO, Reichert M, Ellwart JW, Eick D: Abrogation of p53-induced cell cycle arrest by c-Myc: Evidence for an inhibitor of p21WAF1/CIP1/SDI1. Oncogene 11:1409, 1995